Introduction
============

Colorectal cancer (CRC) is the third most commonly occurring cancer in men and the second most common cancer in women. More than 1.8 million new cases were diagnosed in 2018. Approximately 20% of new colorectal cancer cases are metastatic at the time of diagnosis and another 20% of cases develop into metastatic colorectal cancer (mCRC), which has a significantly lower survival rate \[[@goaa022-B1], [@goaa022-B2]\]. In recent decades, monoclonal antibodies (mAbs) targeting vascular endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) have been used as the first-line treatments for mCRC \[[@goaa022-B3], [@goaa022-B4]\]. Studies indicate that, in the first-line treatment setting, addition of an anti-VEGF antibody therapy improves the median overall survival (OS) \[[@goaa022-B5]\]. However, unlike VEGF inhibitors, the efficacy of anti-EGFR agents, such as cetuximab and panitumumab, is limited to patients with wild-type (wt) V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (*KRAS*) tumors without the V-raf murine sarcoma viral oncogene homolog B1 (*BRAF*) mutation. Given the poor prognosis of *BRAF*- and *KRAS*-mutant mCRC, here, we focus on the *BRAF* and *KRAS* mutations, which exhibit two consensus subtypes.

*KRAS*, *NRAS*, and *HRAS* are some of the most well-studied rat sarcoma virus (RAS) subfamily proteins because of their significant role in cancer \[[@goaa022-B6]\]. Of these *RAS* mutations, *KRAS* mutations (85%) are observed most frequently, followed by *NRAS* (15%) and *HRAS* (1%). *KRAS* mutations occur in approximately 44% of mCRC, with the majority observed in codons 12 and 13 of exon 2 (80% are G12D, G12V, G12C, G12A, and G13D) and less commonly in codon 61 of exon 3 (5% are Q61H, Q61L, and Q61R) and codon 146 of exon 4 (2% are A146T and A146V) \[[@goaa022-B7]\]. Analyses of clinical-trial data strongly suggest that *KRAS* codon 12 or 13 mutations are a major predictive biomarker for resistance to anti-EGFR therapy in patients with mCRC \[[@goaa022-B8]\]. These sites play a part in the activation of v-Raf murine sarcoma viral oncogene (RAF) kinases and mutations in these sites cause constitutive KRAS activation (without ligand-receptor binding), producing resistance to anti-EGFR agents \[[@goaa022-B11], [@goaa022-B12]\].

*NRAS*, the RAS homolog, has identical effector binding domains to *KRAS*. NRAS protein is part of the mitogen-activated protein kinase (MAPK) cascade \[[@goaa022-B13], [@goaa022-B14]\]. Membrane-bound NRAS proteins (189 amino acids) have GTPase activity and play a role in cell-signal transduction. Mutations in *NRAS* may result in structural activation and increased affinity for downstream effectors of the MAPK-signaling pathway---a key event in many cancers. Hence, *NRAS* mutations in codons 12, 13, 61, and 146 yield similar effects to *KRAS* activation \[[@goaa022-B15]\]. *NRAS* mutations also have predictive value in anti-EGFR treatment resistance. Randomized clinical trials have shown that *NRAS* mutations in exons 2, 3, and 4 can be predictive markers of a lack of clinical benefit of anti-EGFR treatment when given in combination with chemotherapy in the first-line setting \[[@goaa022-B14]\]. Patients bearing wt-*RAS* CRC treated with anti-EGFR therapy showed higher response rates and OS than those with *RAS* mutations (*KRAS* and *NRAS* exons 2, 3, and 4) \[[@goaa022-B18]\]. Patients with mCRC with mutations in *NRAS* exons 2, 3, and 4 showed a poor overall response rate (ORR) and an adverse effect on progression-free survival (PFS) and OS \[[@goaa022-B18], [@goaa022-B21], [@goaa022-B22]\]. In another study, patients with *NRAS* mutations developed more distant metastases and the 3-year risk in patients with *NRAS* mutations was 40.0% compared with 12.2% in patients with wt *NRAS* \[[@goaa022-B23]\], indicating the significance of *NRAS* mutations in patients with CRC.

*BRAF* belongs to the RAF family of kinases, which also includes *ARAF* and *CRAF* \[[@goaa022-B24]\]. *BRAF* mutations are less frequent than *KRAS* mutations in mCRC: ∼10% of patients with mCRC bear mutations in *BRAF*. A single substitution missense mutation in V600 comprises approximately 90% of these *BRAF* mutations and nearly 90% of V600 mutations involve substitution to glutamic acid (V600E) \[[@goaa022-B25], [@goaa022-B26]\]. V600 is necessary for *BRAF* to remain inactive in the absence of an activation signal from RAS. The V600E substitution results in constitutive MAPK phosphorylation and subsequent RAF-mitogen-activated protein kinase (MEK)-extracellular signal-regulated kinase (ERK) signal transduction \[[@goaa022-B27]\]. *BRAF* mutations are associated with poor prognosis in mCRC and mortality is nearly triple that of patients with wt-*BRAF* \[[@goaa022-B30], [@goaa022-B31]\].

Over the past two decades, the molecular characterization of mCRC has been revolutionized by the implementation of routine *KRAS*- and *BRAF*-mutation testing. Reportedly, *BRAF* and *KRAS* mutations are associated with a very poor prognosis. In terms of treatment, patients with these mutations show poor response to anti-EGFR treatment \[[@goaa022-B32], [@goaa022-B33]\]. Studies analysing the *KRAS*- and *BRAF*-mutation status of patients with mCRC found that patients with these mutations had lower PFS and OS rates than those with wt-*KRAS* and *BRAF*. Therefore, identification of *BRAF* or *KRAS* mutations can play an important role in improving the response rate and survival in mCRC treatment.

Although, with the advancement in systemic chemotherapy, targeted therapies, and surgical techniques, the survival of patients with mCRC has been improved in the past two decades, a few patients show poor response to treatment and continue to have a poor prognosis; particularly, patients with *BRAF* and *KRAS* mutations show a poor response and inferior survival. Thus, this review will focus on recent advances in personalized therapies for *BRAF*- and *KRAS*-mutant mCRC. Here, we discuss the mechanisms of *BRAF* and *KRAS* mutations that cause resistance to targeted therapies and propose future perspectives for personalized therapy for these patients.

*KRAS* and *BRAF* mutations as prognostic and predictive biomarkers in mCRC treatment
=====================================================================================

mAbs that target EGFR can achieve antitumor efficacy and are used as part of the standard treatment for mCRC. However, in clinical trials comparing therapeutic strategies plus anti-EGFR agents cetuximab or panitumumab, the outcomes are not satisfactory \[[@goaa022-B5]\]. As shown in [Table 1](#goaa022-T1){ref-type="table"}, PFS and OS were reduced in patients treated with an anti-EGFR agent compared with those in patients treated without this agent. In the CAIRO2 trial, patients received either capecitabine--bevacizumab (CB) or capecitabine--bevacizumab--cetuximab (CBC). The addition of cetuximab significantly decreased the median PFS and OS \[[@goaa022-B34]\]. The PACCE study, a phase III trial, evaluated the efficacy of oxaliplatin--bevacizumab (OB) and irinotecan--bevacizumab (IB), with or without panitumumab. Both PFS and OS improved following OB/IB treatment than following OBP/IBP treatment \[[@goaa022-B35]\]. Both these phase III studies (CAIRO2 and PACCE) indicate that the addition of an anti-EGFR antibody resulted in an inferior outcome.

###### 

Effect of treatment with anti-EGFR agents for patients with mCRC harboring *BRAF* or *KRAS* mutations

  Trial        Treatment      PFS (95% CI, months)   OS (95% CI, months)
  -------- ------------------ ---------------------- ---------------------
  CAIRO2           CB         10.7 (9.7--12.3)       20.3 (17.8--24.7)
  CBC       9.4 (8.4--10.5)   19.4 (17.5--21.4)      
  PACCE            OB         11.4 (10.5--11.9)      24.5 (20.4--24.5)
  OBP       10.0 (8.9--11.0)  19.4 (18.4--20.8)      
  IB        11.7 (9.0--13.2)  20.5 (19.8 to NE)      
  IBP       10.1 (8.2--13.7)  20.7 (17.8 to NE)      

CB, capecitabine--bevacizumab; CBC, capecitabine--bevacizumab--cetuximab; OB, oxaliplatin-based chemotherapy and bevacizumab; OBP, oxaliplatin-based chemotherapy, bevacizumab, and panitumumab; IB, irinotecan-based chemotherapy and bevacizumab; IBP, irinotecan-based chemotherapy, bevacizumab, and panitumumab; NE, not estimable.

Given these unexpected results and the results of studies at the preclinical and clinical levels, which suggest that the presence of mutated *KRAS* or *BRAF* is a predictive marker of anti-EGFR resistance \[[@goaa022-B29], [@goaa022-B36]\], we analysed the *KRAS*- and *BRAF*-mutant status and corresponding PFS and OS of each treatment group across several trials ([Table 2](#goaa022-T2){ref-type="table"}). In these trials, the PFS and OS are lower in patients with *KRAS* and *BRAF* mutations than in patients with wt-*KRAS* and *BRAF* when undergoing anti-EGFR treatment. \[[@goaa022-B34], [@goaa022-B35], [@goaa022-B46]\]. The effects of treatment without an anti-EGFR agent are greater than those with an anti-EGFR agent in patients with *KRAS* and *BRAF* mutations. In addition, one study in particular reported that, out of 79 patients with CRC, 11 had *BRAF* mutations and none of these 11 patients responded to anti-EGFR treatment \[[@goaa022-B37]\].

###### 

Clinical trials of the effect of treatment with anti-EGFR agents for patients with mCRC harboring *BRAF* or *KRAS* mutations

  Name of study    Mutated gene type  Phase of clinical trial   No. of patients       Therapeutic strategy   Patients with *KRAS*/ *BRAF* mutations   PFS (months)  OS (months)                                             
  --------------- ------------------- ------------------------- -------------------- ---------------------- ---------------------------------------- -------------- ------------- ------ ------ ------ ------ ------ ------ ------
  PACCE                 *KRAS*        III                       664                          OB/OBP                           260                          39       9.8           11.5   10.4   11.0   20.7   24.5   19.3   19.3
  201                   IB/IBP        86                        43                            10.0                            12.5                        8.3       11.9          NE     19.8   17.8   20.5                 
  CAIRO2                  III         520                       CB/CBC                        206                              40                         10.5      10.6          8.1    12.5   21.8   22.4   17.2   24.9   
  CRYSTAL                 III         1,063                     FOLFIRI, cetuximab            397                              37                         9.9       8.4           7.4    7.7    23.5   20.0   16.2   16.7   
  PRIME                               III                       1,096                 FOLFOX4, panitumumab                    440                          40       9.6           8.0    7.3    8.8    23.9   19.7   15.5   19.3
  CRYSTAL               *BRAF*        III                       519                    FOLFIRI, cetuximab                      45                         8.7       10.4          12.2   6.6    5.9    21.5   24.6   15.2   15.0
  TAILOR                              III                       393                    FOLFOX4, cetuximab                      52                          13       9.3           7.5    2.0    3.8    --     --     --     --

NE, not estimable; OB, oxaliplatin-based chemotherapy, bevacizumab; OBP, oxaliplatin-based chemotherapy, bevacizumab, panitumumab; IB, irinotecan-based chemotherapy, bevacizumab; IBP, irinotecan-based chemotherapy, bevacizumab, panitumumab; CB, capecitabine, oxaliplatin, bevacizumab; CBC, capecitabine, oxaliplatin, bevacizumab, cetuximab; FOLFIRI, irinotecan, infusional fluorouracil, leucovorin; FOLFOX4, infusional fluorouracil, leucovorin, and oxaliplatin.

Several clinical trials demonstrated that mutated *KRAS* and *BRAF* genes are predictive markers of outcomes in mCRC treatment ([Table 3](#goaa022-T3){ref-type="table"}). In addition to the trials discussed above, the table includes several trials that indicate the predictive effect of *BRAF* and *KRAS* mutations \[[@goaa022-B18], [@goaa022-B31], [@goaa022-B34], [@goaa022-B46], [@goaa022-B48]\]. These trials clearly demonstrated that the mutation statuses of *BRAF* and *KRAS* were predictors of outcome for mCRC patients when undergoing anti-EGFR treatment. Patients harboring *BRAF* or *KRAS* mutations showed poor prognosis and lower survival in mCRC.

###### 

*BRAF* and *KRAS* mutations as prognostic factors in clinical studies of first-line treatment for mCRC

  Name of study                                                                                                                                                          Phase of clinical trial   Therapeutic strategy     Key outcomes in patients                                                                                                                                                     Prognostic finding
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------- ------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------
  MRC COIN                                                                                                                                                               III                       OFC                      Median OS, 8.8 vs 20.1 months for patients with wild-type *BRAF* (*P* \< 0.001); median OS, 14 vs 20.1 months for patients with wild-type *KRAS* (*P* \< 0.001)              *KRAS* and *BRAF* mutations have a strong prognostic effect
  CRYSTAL                                                                                                                                                                III                       FOLFIRI, cetuximab       Median OS, 8.8 vs 20.1 months for patients with wild-type *BRAF* (*P* \< 0.001); median OS, 14 vs 20.1 months for patients with wild-type *KRAS* (*P* \< 0.001)              *KRAS* and *BRAF* mutations are important indicators of poor prognosis
  PRIME                                                                                                                                                                  III                       FOLFOX4, panitumumab     In the mutant *KRAS* stratum, PFS was significantly reduced in the panitumumab--FOLFOX4 arm vs the FOLFOX4 arm; median OS, 15.5 vs 19.3 months, respectively (*P* = 0.068)   *KRAS* testing is important for patients with mCRC
  CAIRO2                                                                                                                                                                 III                       CBC                      Median PFS, 8.1 and 12.5 months in patients with *KRAS*-mutant vs 10.5 and 10.6 months in patients with *KRAS* wild-type tumors in two arms                                  Mutation status of the *KRAS* gene was a predictor of outcome in the cetuximab group
  Median OS, 17.2 and 24.9 months in patients with *KRAS*-mutant tumors vs 21.8 and 22.4 months in patients with *KRAS* wild-type tumors with CB and CBC, respectively                                                                                                                                                                                                                                   
  CAIRO2                                                                                                                                                                 III                       CBC                      Median PFS, 5.9 and 6.6 months in patients with *BRAF*-mutant tumors vs 12.2 and 10.4 months in patients with *BRAF* wild-type tumors in two arms                            *BRAF* mutation was a negative prognostic marker in patients with mCRC
  Median OS, 15.0 and 15.2 months in *BRAF*-mutant vs 24.6 and 21.5 months in *BRAF* wild-type tumors in two arms                                                                                                                                                                                                                                                                                        
  NORDIC-VII                                                                                                                                                             III                       Nordic FLOX, cetuximab   ORRs, 20% in patients with *BRAF*-mutant tumors vs 50% in those with *BRAF* wild-type tumors (*P* \< 0.01)                                                                   Presence of *BRAF* mutations was a strong negative prognostic factor
  TAILOR                                                                                                                                                                 III                       FOLFOX-4, cetuximab      Median PFS, 2.0 in patients with *BRAF*-mutant tumors vs 9.3 months in patients with *BRAF* wild-type tumors                                                                 Mutation status of the *BRAF* gene was a predictor of outcome in the cetuximab group
  Pooled analysis of CAIRO, CAIRO2, COIN, and FOCUS phase 3 studies                                                                                                      III                       CBC                      Median PFS, 6.2 in *BRAF*-mutant vs 7.7 months in *BRAF* wild-type tumors                                                                                                    *BRAF*-mutant status was a biomarker conferring poor prognosis in mCRC
  Median OS, 11.4 in *BRAF*-mutant vs 17.2 months in *BRAF* wild-type tumors                                                                                                                                                                                                                                                                                                                             

BRAF, V-raf murine sarcoma viral oncogene homolog B1; KRAS, V-Ki-ras2 Kirsten ratsarcoma viral oncogene homolog; OFC, oxaliplatin, fluoropyrimidine, cetuximab; FOLFIRI, irinotecan, infusional fluorouracil, leucovorin; FOLFOX4, infusional fluorouracil, leucovorin, and oxaliplatin; CBC, capecitabine, oxaliplatin, bevacizumab, cetuximab.

Based on the clinical-trial data shown in [Figure 1](#goaa022-F1){ref-type="fig"} \[37\], we can conclude that patients with mCRC bearing *BRAF* and *KRAS* mutations have poor prognosis with anti-EGFR therapies, which make *KRAS* and *BRAF* mutations prognostic and predictive biomarkers in anti-EGFR combined mCRC-treatment regimens \[[@goaa022-B37]\]. In addition, some studies report that the *BRAF* mutation and the *RAS* mutation are mutually exclusive in mCRC \[[@goaa022-B29], [@goaa022-B53], [@goaa022-B54]\]. None of the patients bearing the *KRAS* mutation carried the associated *BRAF* mutation in these trials. In other words, the *BRAF* mutation occurred exclusively in wt-*KRAS* mCRC.

![*KRAS* and *BRAF* mutations are prognostic and predictive biomarkers in anti-EGFR combined regimens for mCRC treatment. *KRAS* and *BRAF* mutations are associated with poor response to treatment with anti-EGFR. In the sample set, none of the patients harboring the *KRAS* mutation carried the associated *BRAF* mutation, indicating their exclusive relationship in mCRC. The data in the figure are from a clinical trial mentioned in the corresponding part of the text \[37\].](goaa022f1){#goaa022-F1}

The mechanism of anti-EGFR-therapy resistance in *BRAF*- and *KRAS*-mutant mCRC
===============================================================================

*KRAS*, *NRAS*, and *BRAF* are the most-studied mutant genes in mCRC and current data indicate that mutation status is associated with resistance to single-agent cetuximab or panitumumab in patients with mCRC \[[@goaa022-B21], [@goaa022-B55]\]. Randomized studies have shown that patients with mutations in *KRAS* exons 3 and 4 or *NRAS* exons 2, 3, and 4 showed decreased response rates and OS when therapy was combined with an anti-EGFR treatment \[[@goaa022-B18]\]. The *BRAF* mutation is also a strong indicator of poor prognosis in mCRC; the addition of an anti-EGFR agent had a detrimental effect on survival in *BRAF*-mutant patients with mCRC \[[@goaa022-B18], [@goaa022-B56], [@goaa022-B57]\]. Only 10% of patients with chemotherapy--refractory mCRC achieve a positive response to anti-EGFR agents as a single agent \[[@goaa022-B58], [@goaa022-B59]\]. It seems that molecular alterations in the nodes of the EGFR-signaling pathway contribute to primary resistance to anti-EGFR treatment. Given that gene-expression signatures that correspond to *KRAS*, *BRAF*, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (*PIK3CA*)-activating mutations have predictive value on the efficacy of anti-EGFR therapy, downstream components of *KRAS*, *BRAF*, and *PIK3CA* play important roles in anti-EGFR resistance \[[@goaa022-B60]\].

Normally, EGF selectively binds to EGFR and triggers the receptor to form a dimer that activates receptor tyrosine kinase (RTK) activity and RAS ([Figure 2](#goaa022-F2){ref-type="fig"}). RAS is a membrane-bound GTPase that cycles between an inactive guanosine diphosphate (GDP)-bound form and an active guanosine triphosphate (GTP)-bound form. As a binary cell switch, RAS protein is activated by extracellular stimulation \[[@goaa022-B63]\]. KRAS is located on the inner surface of the cell membrane and it transmits signals from activated transmembrane receptor EGFR to effectors in the MAPK and type I phosphatidylinositol 3-kinase (PI3K)/v-aktmurinethymomaviral oncogene (AKT)-signaling pathway in the cytoplasm \[[@goaa022-B10], [@goaa022-B67]\]. On one side, active GTP-bound RAS binds to the three closely related RAF proteins, CRAF1, BRAF, and ARAF, causing RAF to be relocated to the plasma membrane, triggering engagement of the pathway \[[@goaa022-B68], [@goaa022-B69]\]. Activated RAF changes the phosphorylation status and activates MEK1 and MEK2. MEK are capable of phosphorylating and activating the MAPK extracellular signal-regulated kinases 1 and 2 (ERK1 and ERK2) and regulate the activity of several transcription factors that induce the expression of multiple genes involved in cell survival and proliferation \[[@goaa022-B70]\]. The other effector pathway is the PI3K/AKT pathway. RAS can interact directly with the catalytic subunit of PI3Ks. PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate to produce phosphatidylinositol 3,4,5-trisphosphate that can bind to a large number of proteins as a second messenger through the pleckstrin homology domain and other domains such as AKT \[[@goaa022-B73], [@goaa022-B74]\].

![The downstream signaling pathway of the EGFR mainly. EGF selectively binds to EGFR and triggers the receptor to form a dimer that activates RAS. RAS transmits signals from activated transmembrane receptor EGFR to effectors in the MAPK- andPI3K/AKT-signaling pathway in the cytoplasm. Active GTP-bound RAS triggers RAF to engage in signal transmission. Activated RAF changes the phosphorylation status and activates MEK1 and MEK2. MEK are capable of phosphorylating and activating the MAPK extracellular signal ERK1 and ERK2, and regulate cell survival and proliferation. The other effector pathway is the PI3K/AKT pathway. RAS can interact directly with the catalytic subunit of PI3Ks and activate it; activated PI3Ks trigger AKT participate in signal transmission.](goaa022f2){#goaa022-F2}

Constitutive activation of the MAPK-signaling pathway is a major cause of resistance to anti-EGFR therapies in *KRAS*- and *BRAF*-mutant mCRC. Mutations of the *RAS* genes themselves, most frequently *KRAS* mutations, contribute to aberrant signaling through the RAS pathways. This weakens the GTPase-activating proteins (GAPs) and increases the intrinsic catalytic rate of GTPase and prevents the hydrolysis of GTP to GDP, causing an accumulation of active GTP-bound RAS. Accumulation of GTP-bound RAS leads to constitutive KRAS activity, triggering downstream signal transduction and promoting survival and proliferation of the cancer cell. Almost all RAS activation in tumors is caused by mutations in codons 12, 13, and 61 \[[@goaa022-B7], [@goaa022-B75]\]. As a downstream signaling protein of RAS, RAF kinases normally play an important role in the EGFR-mediated MAPK pathway \[[@goaa022-B13], [@goaa022-B24]\]. Some (4%--15%) of mCRC tumors bear *BRAF* mutations and most of them are V600E amino-acid substitutions \[[@goaa022-B11], [@goaa022-B25]\]. As a central amino acid in the kinase domain, V600 is required to maintain RAF in its inactive conformation without RAS activation. Mutations in *BRAF* V600 can constitutively activate the MAPK pathway, regardless of whether RAS is activated or not, resulting in anti-EGFR resistance \[[@goaa022-B54]\]. This receptor-independent pathway activation makes cancerous cells unresponsive to anti-EGFR molecules.

Furthermore, alterations in additional nodes of the EGFR pathway also appear to confer primary anti-EGFR resistance. Studies have demonstrated that mutations in *PIK3CA* exon 20 and phosphatase and tensin homolog (*PTEN*) alterations frequently coexist with *RAS* mutations. These alterations are associated with resistance to anti-EGFR mAbs \[[@goaa022-B62], [@goaa022-B80]\]. Amplification of *KRAS* and the MET receptor have been shown to bypass EGFR signaling and activate the EGFR pathway \[[@goaa022-B81]\]. MET signaling seems to have a synergistic effect on the EGFR pathway in promoting the growth of tumor cells \[[@goaa022-B84]\]. Moreover, the extensive crosstalk among the ERBB (also known as HER) family of receptors can up-regulate parallel pathways as a compensatory adaptive mechanism when EGFR is inhibited. EGFR can form heterodimers with the receptor tyrosine-protein kinase erbB-3 (HER3) and active the downstream PI3K- and MAPK-signaling pathways \[[@goaa022-B85]\].

Subsequent studies found that some patients with wt-*KRAS* and wt-*BRAF* mCRC initially respond to anti-EGFR therapies; a few patients experience disease progression eventually. This is indicative of acquired resistance to anti-EGFR therapy. The most common mechanisms that drive secondary resistance to anti-EGFR agents are genetic alterations that contribute to primary resistance: *KRAS*, *NRAS*, *BRAF*, and *PIK3CA* mutations. These mutations were found in biopsies of patients who experienced relapse, although these mutations were not observed in patients at the beginning of treatment \[[@goaa022-B88]\]. Biopsies confirmed that the number of mutant alleles increased under drug exposure and became undetectable after drug withdrawal \[[@goaa022-B92]\]. Another mechanism of secondary-resistance acquisition is the prevention of drug binding to the receptor by acquired *EGFR* extracellular domain mutations (exon 12). S492R, a particular acquired *EGFR* mutation, is associated with secondary resistance to cetuximab in mCRC. The S492R mutation within the EGFR ectodomain perturbs the conformational state of the kinase drug-binding sites and the resulting bulky side-chain structure at this position could interfere with cetuximab binding \[[@goaa022-B93]\]. *ERBB2* gene upregulation has also been proposed as a factor of secondary resistance to anti-EGFR therapies in wt-*RAS* and wt-*BRAF* mCRC. Activated HER2 signaling in cancer cells can promote *HER2* transcription or upregulate the HER2/HER3 ligand heregulin, thus conferring resistance to anti-EGFR therapies \[[@goaa022-B96], [@goaa022-B97]\].

Emerging therapies targeting *BRAF*-mutant mCRC
===============================================

Combining *BRAF* and EGFR inhibitors
------------------------------------

*BRAF* mutations commonly occur in melanoma and the *BRAF* inhibitor vemurafenib elicits a good response in 60%--80% of patients with *BRAF*-mutant melanoma in clinical trials \[[@goaa022-B98], [@goaa022-B99]\]. Trials testing the efficacy of this *BRAF* inhibitor in the treatment of *BRAF*-mutation-bearing patients with mCRC indicated that vemurafenib gives a poor prognosis for this type of patient \[[@goaa022-B100], [@goaa022-B101]\]. Further investigation revealed that the resistance is induced by reactivation of the *CRAF*-mediated MAPK signal. As shown in [Figure 3](#goaa022-F3){ref-type="fig"}, when *BRAF*--MEK--ERK signaling is interrupted by the *BRAF* inhibitor, the signaling output from mutant *BRAF* is blocked, causing transient suppression of ERK activation. ERK-dependent negative feedback activates EGFR, causing RAF protein dimer formation and reactivation of the *CRAF*-mediated MAPK signaling, which can bypass the *BRAF* node \[[@goaa022-B27], [@goaa022-B67], [@goaa022-B98]\]. On the one hand, this mechanism explains why the single *BRAF* inhibitor has an antitumor effect in melanoma but not in mCRC. Melanoma cells express low levels of EGFR, so they are not influenced by this feedback activation and therefore demonstrate a good response to the single-agent *BRAF* inhibitor \[[@goaa022-B98]\]. In contrast, these findings suggest that there is a strong dependency on MAPK signaling in mCRC and adequate inhibition of this pathway may improve response to treatment. A combination of *BRAF* inhibitors and anti-EGFR mAbs has been shown to produce sustained suppression of MAPK signaling and overcome EGFR-driven resistance *in vitro* and in xenograft models \[[@goaa022-B102]\]. This indicates that doublet-targeted therapy may overcome the feedback effect. The various combination therapies are shown in [Table 4](#goaa022-T4){ref-type="table"}. A combination of panitumumab (EGFR inhibitor) and vemurafenib (*BRAF* inhibitor) treatment in *BRAF*-mutant mCRC demonstrated antitumor efficacy: PFS was 3.2 months \[95% confidence interval (CI), 1.6--5.3\] and OS was 7.6 months (95% CI, 2.1--not reached). Compared with patients on single-agent vemurafenib or panitumumab, patients undergoing double therapy displayed decreased incidence and severity of acneiform rash (40% of grade 1 and 13% of grade 2), maculopapular rash (13%), palmar-plantar erythrodysesthesia syndrome (7%), papilloma (7%), and cutaneous squamous cell carcinoma/keratoacanthoma (0%), likely due to the opposing effects of vemurafenib (activation) and panitumumab (inhibition) on ERK signaling in epidermal keratinocytes \[[@goaa022-B106]\]. A clinical trial evaluating dabrafenib plus panitumumab reported similar results: the 20 patients enrolled had a median PFS of 3.5 months (95% CI, 2.8--5.8 months) and OS of 13.2 months (95% CI, 6.7--22.0 months) \[[@goaa022-B107]\]. This therapy was well tolerated and the majority of adverse events were grade 1 or 2. The most common adverse events of any grade were acneiform dermatitis (60%), nausea (50%), fatigue (50%), and diarrhea (45%) \[[@goaa022-B107]\]. Other combinations of *BRAF* inhibitors and EGFR inhibitors are also in clinical trial; the PFS for encorafenib plus cetuximab was 3.7 months. The most common treatment-related adverse events were as follows: all grades \[fatigue (46%), infusion-related reaction (35%)\], and grade 3/4 \[fatigue (8%), hypophosphatemia (15%)\] \[[@goaa022-B108]\]. Compared with the PFS of patients treated with singlet *BRAF* inhibitor (2.1 months, 95% CI, 0.4--11.6), the PFS of patients treated with combined *BRAF* and EGFR inhibitors significantly improved \[[@goaa022-B109]\].

![The resistance mechanism of BRAF inhibitors. BRAF inhibition interrupts the RAF--MEK--ERK signaling, releases ERK-dependent negative feedback on the EGFR, and subsequently activates EGFR, formats the RAF protein dimer, then reactivates the CRAF-mediated MAPK signal.](goaa022f3){#goaa022-F3}

###### 

Advanced combining therapies on BRAF-mutated mCRC

  Therapeutic strategy                         Agents investigated                     PFS in the experiment group (months)                  PFS in the control group (months)
  -------------------------------------------- --------------------------------------- -------------------------------------- ----------------------------------------------------------------
  Combining *BRAF* and EGFR inhibitors         Vemurafenib + panitumumab               3.2                                     ∼2 months (standard therapies); 2.1 (singlet *BRAF* inhibitor)
  Dabrafenib + panitumumab                     3.5                                                                            
  Encorafenib + cetuximab                      3.7                                                                            
  Combining *BRAF* and MEK inhibitors          Dabrafenib + trametinib                 3.5                                    
  Combining EGFR and MEK inhibitors            Panitumumab + trametinib                2.6                                    
  Combining *BRAF*, EGFR, and MEK inhibitors   Dabrafenib + trametinib + panitumumab   4.2                                                                2.6/3.5
  Encorafenib + cetuximab + binimetinib        4.3                                     1.5                                    

Combining *BRAF* inhibitors and MEK inhibitors
----------------------------------------------

Studies revealed that *BRAF* inhibitors can interrupt the signaling output from mutant *BRAF* and reactivate the *CRAF*-mediated MAPK signal, bypassing the *BRAF* node to transmit signaling to MEK. Therefore, MEK inhibitors may suppress the *CRAF*-mediated MAPK pathway. Mature strategies combining the *BRAF* inhibitor dabrafenib and MEK inhibitor trametinib have been successful in *BRAF*-mutant melanoma and *BRAF*-mutant non-small-cell lung cancer (NSCLC), and significantly improved outcomes compared with those patients treated with dabrafenib alone \[[@goaa022-B2], [@goaa022-B110]\]. The doublet combination of dabrafenib and trametinib for *BRAF*-mutant mCRC has also been trialed in clinic. Combined dabrafenib and trametinib contribute to an improved response rate (median PFS, 3.5 months; 95% CI, 3.4--4.0 months). In terms of safety, 17 adverse events (40%) led to a dose reduction, 25 adverse events (58%) led to a dose interruption, and four patients (9%) discontinued treatment due to an adverse event \[[@goaa022-B115]\]. Another clinical trial of the same drug combination reported similar results. At data cut-off, 3-year PFS rate was 22% for the doublet-treatment group and 12% for the singlet-treatment group (HR, 0.71; 95% CI, 0.57--0.88), and the 3-year OS rate was 44% and 32%, respectively (HR, 0.75; 95% CI, 0.58--0.96). The incidence of adverse events was higher (\>10% difference, any grade) in the doublet-treatment group than in the singlet-treatment group: pyrexia (59% vs 33%), chills (32% vs 17%), diarrhea (31% vs 17%), vomiting (26% vs 15%), and peripheral edema (22% vs 9%) \[[@goaa022-B116]\]. Combining *BRAF* and MEK inhibitors has similar efficacy to combining *BRAF* and EGFR inhibitors, and results in improved PFS compared with singlet *BRAF* inhibitors.

Combining EGFR inhibitors and MEK inhibitors
--------------------------------------------

Combined MEK and EGFR inhibition with trametinib and/or panitumumab for *BRAF*-mutant mCRC has also been trialed in clinic. No patient in the trametinib-plus-panitumumab-treatment group achieved complete or partial response and 55% were stable (T + P, *n *=* *31), whereas, in the dabrafenib-plus-panitumumab-treatment group (D + P, *n *=* *20), 10% had a confirmed complete or partial response and 80% were stable. The triplet-treatment group (D + P plus trametinib, *n *=* *91) resulted in a confirmed complete response or partial response in 21% of patients, stable disease in 65%, and an overall disease-control rate of 86%. The median PFS in the trametinib-plus-panitumumab group was 2.6 months (95% CI, 1.4--2.8 months) compared with 3.5 months (95% CI, 2.8--5.8 months) in the D + P group and 4.2 months (95% CI, 4.0--5.6 months) in the D + P plus trametinib group. These results suggest that combination therapy of *BRAF* and EGFR inhibitors may not be a priority in *BRAF*-mutant mCRC \[[@goaa022-B107], [@goaa022-B117]\].

The triplet chemotherapy of *BRAF*, EGFR, and MEK inhibitors
------------------------------------------------------------

A clinical trial compared the combination of dabrafenib and panitumumab with or without trametinib in 120 patients with *BRAF*-mutant mCRC. PFS was 4.2 months (95% CI, 4.0--5.6 months) in the triplet-treatment group and 3.5 months (95% CI, 2.8--5.8 months) in the treatment group without trametinib \[[@goaa022-B107]\]. A large phase III trial involving only patients with *BRAF*--V600E-mutated mCRC was recently reported. A total of 665 patients were divided into three equal groups: triple-therapy group (encorafenib, binimetinib, and cetuximab), double-therapy group (encorafenib and cetuximab), and a control group (the investigators' choice of either cetuximab and irinotecan or cetuximab and FOLFIRI). The therapeutic effect was significant; the median OS was 9.0 months (95% CI, 8.0--11.4) in the triple-therapy group, 8.4 months (95% CI, 7.5--11.0) in the double-therapy group, and 5.4 months (95% CI, 4.8--6.6) in the control group. Additionally, the risk of death was significantly lower (by 48%) in the triple-therapy group than in the control group (HR, 0.52; 95% CI, 0.39--0.70; *P *\<* *0.001). The PFS was significantly longer in both the triple-therapy group and the double-therapy group than in the control group: the median PFS was 4.3 months (95% CI, 4.1--5.2) in the triple-therapy group, 4.2 months (95% CI, 3.7--5.4) in the double-therapy group, and 1.5 months (95% CI, 1.5--1.7) in the control group \[[@goaa022-B118]\]. Importantly, no increase in skin toxicity or fatigue was observed with the triple combination and no new safety signals were noted.

Standard therapies have limited benefit for *BRAF*-mutation-bearing patients with mCRC with a PFS of approximately 2 months and an OS of 4--6 months \[[@goaa022-B118]\]. Double and triple therapies can both prolong PFS; triple therapy combining BRAF, EGFR, and MEK inhibitors remarkably delivers a much longer PFS than the double therapy ([Table 4](#goaa022-T4){ref-type="table"}).

Combination of MEK inhibitors and ERK inhibitors
------------------------------------------------

Studies have evaluated molecular alterations in the MAPK pathway after treatment with a BRAF/EGFR inhibitor or *BRAF*/MEK inhibitor in *BRAF*-mutant mCRC \[[@goaa022-B29]\]. The mechanism of resistance involved *KRAS* mutation, *KRAS* upregulation, *BRAF* upregulation, and *MEK1* mutation. The use of MEK inhibitors triggers *KRAS* mutation, *KRAS* upregulation, and *BRAF* upregulation, thus increasing the pathway flux and promoting MEK hyperactivation that can overcome the efficacy of MEK inhibitors \[[@goaa022-B38], [@goaa022-B81]\]. Despite upstream MAPK-pathway alterations, ERK inhibitors still have the ability to suppress the reactive MAPK pathway \[[@goaa022-B119], [@goaa022-B120]\]. Studies on the effects of the ERK-inhibitor combination strategy on a *BRAF*-mutant mCRC cell line suggest that the combination of ERK inhibitors and MEK inhibitors is more effective than single treatment \[[@goaa022-B119], [@goaa022-B120]\]. Although ERK inhibitors are at the early stages of clinical trial, they are expected to play an important role in the advanced therapeutic regimen for *BRAF*-mutant mCRC \[[@goaa022-B121]\].

Emerging therapies targeting *KRAS*-mutant mCRC
===============================================

*KRAS* mutations occur in 35%--45% of mCRC, causing therapy resistance and poor prognosis. *KRAS* is regarded as an 'undruggable' oncoprotein that cannot be targeted pharmacologically, so we discuss recent progress in new directions such as the parallel inhibition of the PI3K/AKT and MAPK pathways, directly targeting mutant *KRAS*, targeting *KRAS*-membrane association, exploring the *KRAS*-regulated metabolic pathway, as well as immunotherapy and *KRAS* synthetic lethal interactions \[[@goaa022-B72], [@goaa022-B122]\].

Combination of PI3K inhibitor and MEK inhibitor in preclinical trial
--------------------------------------------------------------------

Although *KRAS* cannot be directly targeted, we can target downstream RAS and parallel signaling pathways. PI3K functions downstream to RTKs, which are regulated by RAS kinases. MEK and PI3K are parallel signaling pathways. Inhibition of the MEK pathway activates the PI3K pathway, and PI3K activation mediates resistance to MEK inhibition \[[@goaa022-B125]\]. A study tested whether combining MEK and PI3L inhibitors can produce a stronger response in a *KRAS*-mutant cell line. The study assessed a combination of an MEK1/2 inhibitor AZD6244 and a PI3K inhibitor BEZ235 *in vivo* and measured the tumor volumes of tumor-bearing mice. Treatment with cetuximab for 3 weeks did not inhibit tumor growth; treatment with AZD6244 or BEZ235 alone caused a ∼50% reduction in tumor growth. Notably, the combined treatment of AZD6244 and BEZ235 completely inhibited tumor growth at the end of the 3-week treatment period. Importantly, there were no signs of weight loss or other acute or delayed toxicity symptoms in either the single-agent- or combination-treatment group \[[@goaa022-B126]\]. This preclinical trial provides convincing evidence that combined PI3K inhibitors and MEK inhibitors enhance antitumor efficacy against *KRAS*-mutant cells, which strongly supports the development of clinical trials for this patient population.

Directly targeting *KRAS*-mutant mCRC
-------------------------------------

RAS is a membrane-bound GTPase that cycles between an inactive GDP-bound form and an active GTP-bound form. RAS protein is activated by extracellular stimulation and is converted to active GTP-bound RAS. *KRAS* G12C is one of the most common *KRAS* mutants in cancer, present in 10%--20% of all *KRAS* G12 mutations. Biochemical analysis showed that KRAS G12 preferentially binds to the inactive GDP-bound form of RAS, impairing SOS-catalysed nucleotide exchange and decreasing the affinity of RAS for GTP, resulting in decreased survival and increased apoptosis of tumor cells containing the G12C oncogene \[[@goaa022-B127]\].

AMG 510, the first KRAS G12C inhibitor in clinical development, has undergone preclinical trial \[[@goaa022-B130]\]. AMG 510 treatment reduced tumor size and, in some cases, even eradicated the tumor in a *KRAS*-mutant murine model. Moreover, AMG 510 has a synergistic effect with chemotherapy, immunotherapy, and other targeted inhibitors such as the MEK inhibitor. In the NCI-H358 tumor-cell line carrying the *KRAS* G12C mutation, AMG 510 had synergistic effects with a MEK inhibitor. *In vivo*, the combination of low-dose AMG 510 and MEK inhibitor significantly improved the antitumor effect compared with single-drug therapy in tumor-bearing mice. Tumor growth was inhibited in singlet-treatment groups compared with the control group, and the tumor volume tended to decrease in the combination-treatment group. These data suggest that the combination of AMG 510 with inhibitors targeting the MAPK-signaling pathway may eliminate bypass or residual signaling, which may in turn enhance efficacy or prevent drug resistance. When AMG 510 is combined with carboplatin, a standard chemotherapy for lung cancer *in vivo*, the combined treatment significantly reduced tumor volume compared with single-drug therapy. Additionally, tumor-bearing mice were treated with suboptimal doses of AMG 510 and/or PD-1 inhibitors, which can upregulate T-cell activity and enhance the T-cell recognition of tumor cells. The results showed that AMG 510 single-drug treatment caused the complete disappearance of the tumor in only 1 of 10 mice and PD-1-inhibitor monotherapy had a similar effect, whereas the combination therapy resulted in the complete disappearance of tumors in 9 of 10 mice. This indicates that AMG 510 has potential as a combination therapeutic agent in *KRAS*-mutant mCRC.

Targeting G-quadruplex (G4) structures of the *KRAS* gene
---------------------------------------------------------

G4 structures are formed in guanine-rich nucleic-acid sequences and play a key role in tumor development through the regulation of a wide range of oncogenes, tumor-suppressor genes, and somatic copy-number alterations \[[@goaa022-B131], [@goaa022-B132]\]. There are three G4 motifs in the human *KRAS* promoter: G4-proximal, G4-middle, and G4-distal. In particular, the G4-middle structure may play an important part in the development of targeted therapeutics \[[@goaa022-B133], [@goaa022-B134]\]. EMICORON, a novel synthetic G4 ligand, has shown promising antitumor efficacy against CRC tumors. In HCT-116 CRC cells, *KRAS* mRNA and protein expression were downregulated after EMICORON treatment, suggesting that EMICORON can downregulate both *KRAS* mRNA and protein expression by targeting the G4 structure. *In vivo*, EMICORON was tested on a panel of patient-derived xenografts (PDXs) bearing *KRAS* mutations. In all three PDXs, the tumor volume of mice treated with EMICORON was decreased compared with that of untreated mice. In addition, no adverse effects were observed in the treated mice. EMICORON can also improve the efficacy of chemotherapy: CRC PDXs treated with EMICORON plus FOLFIRI showed better response rates and survival than the FOLFIRI-alone-treatment group \[[@goaa022-B135], [@goaa022-B136]\]. These results suggest that EMICORON has therapeutic potential for *KRAS-*mutant mCRC.

Potential therapeutic strategies in *KRAS-*mutant mCRC
======================================================

Targeting *KRAS*-membrane association
-------------------------------------

*KRAS* located on the inner leaflet of the plasma membrane transmits signals from activated EGFR transmembrane receptors to downstream cytoplasmic effectors. *KRAS* realizes its oncogenic activity through this membrane association. Therefore, inhibiting *KRAS*-membrane association seems a logical therapy for *KRAS*-mutant cancers \[[@goaa022-B137]\]. Phosphodiesterase-6δ (PDEδ) is a prenyl-binding protein that enriches RAS at the plasma membrane, thus augmenting RAS signaling \[[@goaa022-B138]\]. A small-molecule inhibitor, deltarasin, prevents PDEδ from binding to *KRAS* and impairs *KRAS* localization to the endomembrane. Deltazinone 1, an improved PDEδ inhibitor, showed high selectivity and less nonspecific cytotoxicity than deltarasin and, at the same time, exhibited high correlation with the phenotypic effect of PDEδ knockdown in a set of human pancreatic-cancer-cell lines \[[@goaa022-B139], [@goaa022-B140]\]. However, further chemical optimization is required, as its chemical properties are unstable *in vivo.*

Targeting the KRAS-regulated metabolic pathway
----------------------------------------------

The infinite proliferation of tumor cells requires metabolic reprogramming to produce biomass. *KRAS*-mutant tumors also develop the metabolic pathways to obtain substrates from both extracellular and intracellular sources to meet their metabolic need \[[@goaa022-B141], [@goaa022-B142]\]. *KRAS*-mutant CRC tumors show high expression of glycolytic and glutamic metabolic proteins \[[@goaa022-B143]\]. CB-839---an inhibitor targeting the glutaminase (GLS) that contributes to the conversion of glutamine to glutamate---is currently being evaluated in phase I and II clinical trials for the treatment of various cancers \[[@goaa022-B144]\]. In addition, *KRAS*-mutant cells show glyceraldehyde 3-phosphate dehydrogenase (GAPDH) metabolic vulnerability compared with wt-*KRAS* cells and vitamin C selectively kills *KRAS*-mutant CRC cells by inhibiting GAPDH \[[@goaa022-B145]\].

Immunotherapy and synthetic lethal interactions in *KRAS*-mutant cancer
-----------------------------------------------------------------------

Immunotherapy is a key focus in cancer treatment currently, especially immune-checkpoint-blocking antibodies. Immune-checkpoint-blocking antibodies are profoundly changing the therapeutic strategies of various cancers. Specifically, the anti-PD-1/PD-L1 antibody has shown significant antitumor activity by restoring the T-cell antitumor response. PD-L1 is present in some normal cells as well as cancer cells. When PD-1 is bound to PD-L1, T-cells do not attack the cell. Some cancer cells contain large amounts of PD-L1, allowing them to escape immune attack. mAbs targeting PD-1 or PD-L1 can block this binding and prevent cancer cells from escaping T-cell attack, thereby restoring the normal immune response to cancer cells. Anti-PD-1/PD-L1 antibody treatment is now approved in various tumor types \[[@goaa022-B146]\]. *KRAS*-mutant NSCLC was effectively treated with the PD-1 antibody pembrolizumab combined with the MEK inhibitor trametinib \[[@goaa022-B147]\]. Clinical trials demonstrated that the PD-1 antibody treatment is more effective in patients with *KRAS-*mutant NSCLC than in patients with wt-*KRAS* NSCLC \[[@goaa022-B147], [@goaa022-B148]\]. This is likely because *KRAS* mutations impede DNA repair, especially mismatch repair (MMR), which supports the notion that MMR deficiency is a favorable factor for PD-1 blockade \[[@goaa022-B149]\]. This result suggests that immunotherapy is a promising potential treatment strategy for *KRAS*-mutant mCRC.

Synthetic lethal interactions in *KRAS-*mutant cancer have also been widely studied. Synthetic lethality defines the interaction between two co-essential genes such that inhibiting both genes rather than either single gene can result in cell death \[[@goaa022-B150]\]. There are several stage I and II clinical trials assessing the synthetic lethality of MEK inhibitors combined with BCL2, AKT, or SHP2 in *KRAS-*mutant cancer. These treatments produce antitumor efficacy by interrupting the pathways required for the survival of *KRAS-*mutant cells, including co-operating signaling, transcriptional regulation, and the maintenance of genomic stability \[[@goaa022-B151]\]. We found that most of the synthetic lethality studies in *KRAS-*mutant cancer are focused on specific cancer cell lines or tumor models; however, as *KRAS-*mutant cancers in clinical trials are highly heterogeneous, further studies should aim at systematically examining a spectrum of *KRAS*-mutant cancers.

Combination of curcumin and regorafenib
---------------------------------------

Curcumin is a polyphenol, which is the main yellow pigment in turmeric. Pharmacologically, it has an anticancer effect in human clinical trials by promoting apoptosis and inducing autophagy \[[@goaa022-B154]\]. Additionally, in an ongoing phase III clinical trial, curcumin has been demonstrated to be a safe and effective treatment for patients with CRC \[[@goaa022-B155]\]. Regorafenib is a multityrosine kinase inhibitor that mainly inhibits antigenic and oncogenic kinases, such as VEGFR, PDGFR, FGFR, and BRAF. Two randomized phase III clinical studies (CORRECT and CONCUR) evaluated the efficacy of regorafenib in mCRC treatment and the results indicate that regorafenib is a promising treatment option for patients with mCRC who had poor prognosis \[[@goaa022-B156]\].

Another study found that curcumin had a similar antitumor effect to MEK inhibitor U0126 and that this effect was enhanced when curcumin was used synergistically with regorafenib in the *KRAS*-mutant CRC cell line HCT 116. Inhibiting MEK conferred the synthetic lethal interaction with RAF1 inhibition in a new concept for combination-drug treatments. It may be possible to overcome the limited therapeutic effect of current treatments for *KRAS*-mutant mCRC by developing doublet-combination therapies targeting the RAF--MEK pathway. Given that curcumin has the potential to inhibit MEK and regorafenib is a RAF-targeting agent, we propose that the combination of curcumin and regorafenib is a promising therapeutic strategy for *KRAS*-mutant mCRC \[[@goaa022-B159], [@goaa022-B160]\].

Conclusions
===========

Personalized therapy enables patients to receive maximum treatment efficacy with minimum side effects, ensuring the best possible quality of life and maximum survival of patients. The current approved first-line combination of chemotherapy and anti-EGFR agent treatment that has been highly effective in patients with mCRC clinically has little benefit and poor prognosis when applied to *BRAF*- and *KRAS*-mutation-bearing patients with mCRC. Analysis of the *BRAF*- or *KRAS*-mutant occurrence in no-response-to-anti-EGFR-agents patients and possible resistance mechanisms suggest that *BRAF*- and *KRAS*-mutant statuses are critical prognostic and predictive biomarkers in mCRC treatment. Utilizing this biomarker status to select patients and formulate personalized therapeutic strategies according to oncogene status promises to improve patient outcomes. The addition of an inhibitor of the specific *BRAF* mutation provides additional treatment options that include EGFR inhibitors and increases the likelihood of treatment-delayed disease progression. Combining inhibitors that target specific node kinases such as EGFR inhibitors, BRAF inhibitors, MEK inhibitors, and ERK inhibitors provides promising clinical treatment to delay disease progression and prolong survival times. While no mature inhibitor-targeted therapies for *KRAS*-mutant mCRC have been currently adopted into clinical treatment, data from preclinical and clinical trials indicate potential combination-treatment options for *KRAS*-mutant mCRC patients such as curcumin plus regorafenib or PI3K inhibitor plus MEK inhibitor.
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